| GlaxoSmithKline and Genmab announce start of ofatumumab Phase III combination study |
|
09/09/2010 15:39 (521 Day 04:26 minutes ago) | |||||
|
The FINANCIAL -- GlaxoSmithKline (GSK) and Genmab A/S (OMX: GEN) announced today the start of a Phase III study in patients with indolent B-cell non-Hodgkin’s lymphoma (B-NHL) who did not respond to or progressed during, or within 6 months of a rituximab containing regimen.
Under the terms of Genmab’s collaboration with GlaxoSmithKline (GSK), Genmab will receive a milestone payment of approximately DKK 116 million (approximately USD 20 million), triggered by the treatment of the first patient in the study.
|
|
|
